Ziftomenib, venetoclax, and azacitidine for pediatric leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combination (ziftomenib, venetoclax, and azacitidine) in children and young adults with acute leukemia that has come back or not responded to treatment. It may help if your child's leukemia has certain genetic changes (like KMT2A, NPM1, or NUP98).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 21 years old.
- Your leukemia must have come back or not responded to prior treatment, and have certain genetic markers (like KMT2A, NPM1, or NUP98).
- You need at least 5% blast cells (immature cells) in your bone marrow.
- Your white blood cell count must be below 25,000 before starting the trial (medication is allowed to lower it).
- Your heart, liver, and kidney function must be adequate.
- If you are of childbearing age, you must use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (hyper-CVAD) plus a targeted pill called venetoclax for children and young adults with a type of leukemia that has returned or not responded to treatment. The goal is to see if this combo can help control the leukemia.
This trial tests a new drug, ziftomenib, combined with two standard chemotherapies (venetoclax and gemtuzumab) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells.
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
This trial tests a new targeted drug called ziftomenib combined with chemotherapy for children whose leukemia (with specific genetic changes) has come back or is not responding to treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Refractory Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.